181 related articles for article (PubMed ID: 19762082)
1. Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?
Kovacs E
Leuk Res; 2010 Jul; 34(7):912-6. PubMed ID: 19762082
[TBL] [Abstract][Full Text] [Related]
2. Expression and production of interleukin 10 in human myeloma cell lines.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.
Westendorf JJ; Ahmann GJ; Greipp PR; Witzig TE; Lust JA; Jelinek DF
Leukemia; 1996 May; 10(5):866-76. PubMed ID: 8656685
[TBL] [Abstract][Full Text] [Related]
5. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
6. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
[TBL] [Abstract][Full Text] [Related]
7. [Cytokines and lymphoplasmocytic proliferations: essential role of interleukin 6].
Bataille R; Klein B
Rev Prat; 1993 Feb; 43(3):275-8. PubMed ID: 8502954
[TBL] [Abstract][Full Text] [Related]
8. An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma.
Lu ZY; Bataille R; Poubelle P; Rapp MJ; Harousseau JL; Klein B
Stem Cells; 1995 Aug; 13 Suppl 2():28-34. PubMed ID: 8520508
[TBL] [Abstract][Full Text] [Related]
9. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells.
Cheung WC; Van Ness B
Leukemia; 2002 Jun; 16(6):1182-8. PubMed ID: 12040451
[TBL] [Abstract][Full Text] [Related]
10. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines.
Jernberg H; Pettersson M; Kishimoto T; Nilsson K
Leukemia; 1991 Mar; 5(3):255-65. PubMed ID: 1707469
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.
Lu ZY; Zhang XG; Rodriguez C; Wijdenes J; Gu ZJ; Morel-Fournier B; Harousseau JL; Bataille R; Rossi JF; Klein B
Blood; 1995 May; 85(9):2521-7. PubMed ID: 7727780
[TBL] [Abstract][Full Text] [Related]
13. Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells.
Kang HS; Lee BS; Yang Y; Park CW; Ha HJ; Pyun KH; Choi I
Cell Immunol; 1996 Mar; 168(2):174-83. PubMed ID: 8640863
[TBL] [Abstract][Full Text] [Related]
14. Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines.
Drexler HG; Meyer C; Gaidano G; Carbone A
Leukemia; 1999 Apr; 13(4):634-40. PubMed ID: 10214873
[TBL] [Abstract][Full Text] [Related]
15. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of multiple myeloma cell growth].
Simizu S; Konda S
Rinsho Ketsueki; 1993 Apr; 34(4):418-22. PubMed ID: 8510327
[TBL] [Abstract][Full Text] [Related]
17. Cytokine network in human multiple myeloma.
Klein B; Bataille R
Hematol Oncol Clin North Am; 1992 Apr; 6(2):273-84. PubMed ID: 1582974
[TBL] [Abstract][Full Text] [Related]
18. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma and B cell lymphoma. Investigation of IL-6, IL-6 receptor antagonist (IL-6RA), and GP130 antagonist (GP130A) using various parameters in an in vitro model.
Kovacs E
ScientificWorldJournal; 2006 Aug; 6():888-98. PubMed ID: 16892169
[TBL] [Abstract][Full Text] [Related]
20. C-kit ligand (SCF) in human multiple myeloma cells.
Lemoli RM; Fortuna A
Leuk Lymphoma; 1996 Feb; 20(5-6):457-64. PubMed ID: 8833403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]